

Variants of the *elongator protein 3 (ELP3)* gene are associated with motor neuron degeneration

Claire L. Simpson^{1,†}, Robin Lemmens^{4,†}, Katarzyna Miskiewicz^{6,7}, Wendy J. Broom⁸, Valerie K. Hansen¹, Paul W.J. van Vught⁹, John E. Landers⁸, Peter Sapp^{8,11}, Ludo Van Den Bosch^{4,5}, Joanne Knight³, Benjamin M. Neale³, Martin R. Turner¹, Jan H. Veldink⁹, Roel A. Ophoff^{10,12}, Vineeta B. Tripathi¹, Ana Beleza¹, Meera N. Shah¹, Petroula Proitsi², Annelies Van Hoecke^{4,5}, Peter Carmeliet⁵, H. Robert Horvitz¹¹, P. Nigel Leigh¹, Christopher E. Shaw¹, Leonard H. van den Berg⁹, Pak C. Sham¹³, John F. Powell², Patrik Verstreken^{6,7}, Robert H. Brown Jr⁸, Wim Robberecht^{4,5} and Ammar Al-Chalabi^{1,*}

¹Department of Neurology, ²Department of Neuroscience, MRC Centre for Neurodegeneration Research and ³MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London SE5 8AF, UK, ⁴Service of Neurology (University Hospital Leuven) and Laboratory for Neurobiology, Section of Experimental Neurology, University of Leuven, Leuven B-3000, Belgium, ⁵Vesalius Research Center, Flanders Institute for Biotechnology (VIB) and ⁶Center for Human Genetics, Laboratory of Neuronal Communication, KU Leuven, Leuven B-3000, Belgium, ⁷Department of Molecular and Developmental Genetics, VIB, Leuven B-3000, Belgium, ⁸Cecil B Day Laboratory for Neuromuscular Research, Massachusetts General Hospital East, Charlestown, MA, USA, ⁹Department of Neurology and ¹⁰Department of Medical Genetics, Rudolf Magnus Institute of Neuroscience, University Medical Center, Utrecht, the Netherlands, ¹¹Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA, ¹²Neuropsychiatric Institute, University of California, Los Angeles, CA, USA and ¹³Department of Psychiatry and Genome Centre, University of Hong Kong, Hong Kong

Received September 7, 2008; Revised October 14, 2008; Accepted November 4, 2008

Amyotrophic lateral sclerosis (ALS) is a spontaneous, relentlessly progressive motor neuron disease, usually resulting in death from respiratory failure within 3 years. Variation in the genes *SOD1* and *TARDBP* accounts for a small percentage of cases, and other genes have shown association in both candidate gene and genome-wide studies, but the genetic causes remain largely unknown. We have performed two independent parallel studies, both implicating the RNA polymerase II component, *ELP3*, in axonal biology and neuronal degeneration. In the first, an association study of 1884 microsatellite markers, allelic variants of *ELP3* were associated with ALS in three human populations comprising 1483 people ($P = 1.96 \times 10^{-9}$). In the second, an independent mutagenesis screen in *Drosophila* for genes important in neuronal communication and survival identified two different loss of function mutations, both in *ELP3* (R475K and R456K). Furthermore, knock down of *ELP3* protein levels using antisense morpholinos in zebrafish embryos resulted in dose-dependent motor axonal abnormalities [Pearson correlation: -0.49 , $P = 1.83 \times 10^{-12}$ (start codon morpholino) and -0.46 , $P = 4.05 \times 10^{-9}$ (splice-site morpholino), and in humans, risk-associated *ELP3* genotypes correlated with reduced brain *ELP3* expression ($P = 0.01$). These findings add to the growing body of evidence

*To whom correspondence should be addressed at: MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry P 043, London SE5 8AF, UK. Tel: +44 2078485172; Fax: +44 2078485190; Email: ammar@iop.kcl.ac.uk

†The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.

implicating the RNA processing pathway in neurodegeneration and suggest a critical role for ELP3 in neuron biology and of *ELP3* variants in ALS.

INTRODUCTION

Spontaneous, relentlessly progressive motor neuron degeneration occurs in several diseases of humans. The commonest adult onset human motor neuron disease is amyotrophic lateral sclerosis (ALS), which usually results in death from respiratory muscle weakness within 3 years. In 5–10% of cases there is a family history of ALS and about a quarter of these are attributable to mutation in the *superoxide dismutase* (*SOD1*) or *TAR-DNA binding protein 43* (*TARDBP*) genes. The genetic contribution to sporadic ALS is largely unknown, but candidate gene association studies have revealed *SOD1* mutations in 1–7% of cases and *TARDBP* mutations in 0.5–5% (1–3).

Single-nucleotide polymorphism (SNP) based genome-wide association studies have been inconclusive. One small study has not shown a significant association (4). A larger study using a DNA pooling approach to prioritize SNPs has identified ALS-associated variants in an uncharacterized gene, FLJ10986 (5). By combining with other data sets, a Dutch study has identified ALS-associated variants in the genes *ITPR2* and *DPP6* (6,7). The combination of some of the Dutch study samples with further samples from an Irish population detected *DPP6* as the most strongly associated variant but this did not reach statistical significance (8). Nevertheless, the appeal of genome-wide association studies is that any genetic association will provide an insight that would not be possible with a candidate gene approach. Although SNP-based studies are simple to perform and have excellent genomic coverage, microsatellite-based studies provide an alternative view of the genome and may be more likely to detect rare variants (9). Similarly, mutagenesis in small organisms followed by screening for neurodegeneration phenotypes may reveal genes critical for motor neuron function that are not found by other methods. We therefore performed two independent studies to identify genes important in neuronal function or survival: the first, a microsatellite-based genetic association study of ALS in humans and the second, a mutagenesis screen in *Drosophila*. In both cases, variants of the same gene, *elongator protein 3* (*ELP3*) were identified as critical for axonal biology, and this was supported by further functional studies.

RESULTS

Human association study

Demographic features of the study populations are shown in Supplementary Material, Table S1. We used a multistage design to examine a population from the UK with 1884 microsatellite markers, which were then ranked by strength of association (Supplementary Material, Figs S1–S4) and followed-up by replication studies in two other populations from the USA and Belgium and fine mapping using SNPs. Four markers were followed-up, two on chromosome 3 and

two on chromosome 8, each pair about 1 Mb apart. We used permutation to correct for the multiple testing inherent in examination of multiple microsatellite alleles as instituted in the program CLUMP. Alleles of D8S1820, a 15-allele marker, were associated with ALS ($P = 1.96 \times 10^{-9}$) (Supplementary Material, Table S2). At the end of the permutation procedure, CLUMP had grouped the alleles of D8S1820 into two groups: alleles 1, 6, 10, 14 and 15 (hereafter called the protection-associated alleles), and the remaining alleles (hereafter called the risk-associated alleles) (Supplementary Material, Table S3). To better understand the risk associated with the two allelic groups, we performed a $2 \times 2 \chi^2$ test for independence of the allelic groups with ALS. We again confirmed a highly significant association in an overall analysis stratified for the populations, with an odds ratio of 0.46, 95% CI 0.35–0.60, $P = 8.94 \times 10^{-9}$ (Table 1). Each study population also showed the association with a similar odds ratio (Breslow–Day test for homogeneity $P = 0.42$). Bioinformatics analysis with the programs ePCR and BLAT confirmed a unique location of D8S1820 in intron 10 of the *ELP3* gene.

The extent of genomic coverage by our microsatellite selection is difficult to estimate. The markers had a mean spacing of 1.5 Mb and a median spacing of 0.67 Mb covering all autosomes and the X chromosome, 46% targeted to candidate regions and 54% targeted to gene-dense regions, but we expect that there will be large genomic regions not included in this analysis.

The relationship of linkage disequilibrium between SNPs and microsatellite alleles is complex and often weak for some alleles, but may extend long distances (9). Consequently, translating a microsatellite allelic association into an SNP or haplotype association can be difficult. To examine patterns of linkage disequilibrium in the region as a prelude to fine mapping, we analyzed D8S1820 alleles in the Utah CEPH (CEU) HapMap samples (<http://www.hapmap.org>). As expected, we observed a complex pattern of linkage disequilibrium with neighbouring SNPs (data not shown).

To search for a functional variant, we selected 61 tag-SNPs in and around the *ELP3* gene for fine-mapping studies in the study populations (Supplementary Material, Table S4). We observed the same linkage disequilibrium pattern in each population (Fig. 1, Supplementary Material, Figs S5 and S6). One SNP, rs13268953, showed weak association with ALS (stratified $P = 0.029$, unstratified $P = 0.030$), but this did not survive Bonferroni correction for multiple testing, nor was it significantly associated with ALS in the individual study populations. No other SNPs showed association.

To search for a haplotypic association, we first simplified the microsatellite information by examination of the individual allelic associations. This showed that the signal came most strongly from allele 6, which was under-represented in cases compared with controls (case frequency 0.027, controls 0.057). We then sought a two-marker haplotype with allele 6, testing each SNP in turn using the omnibus haplotype test

Table 1. Alleles of marker D8S1820 as grouped by CLUMP, analyzed by χ^2 test

	Allelic ratios (cases, controls; protection-associated: risk-associated)	Odds ratio (95% CI)	P-value	n (cases, controls)
UK	36:538, 64:516	0.54 (0.35–0.83)	0.004	287, 290
USA	45:563, 60:344	0.46 (0.30–0.69)	1.41×10^{-4}	304, 202
Belgium	12:368, 39:381	0.32 (0.16–0.62)	3.96×10^{-4}	190, 210
Total: stratified test	<i>As for each country</i>	0.46 (0.35–0.60)	8.95×10^{-9}	781, 702
Total: unstratified test	93:1469, 163:1241	0.48 (0.37–0.63)	4.34×10^{-8}	781, 702

Counts and association results for alleles of marker D8S1820 analyzed as a bi-allelic system of protection-associated alleles against risk-associated alleles. Alleles were classified after permutation testing by CLUMP.




Figure 1. A scatterplot of the linkage disequilibrium between common alleles of microsatellite D8S1820 and neighboring SNPs in controls of the study population. The position of the *ELP3* gene is shown as a red bar below the X-axis. Marker D8S1820 is marked by the central vertical arrow and rs12682496 by the right vertical arrow. Because of the multi-allelic nature of microsatellite markers it is difficult to show patterns of LD using the conventional triangle plots used for SNPs (but see Supplementary Material, Figs S5 and S6). This graph plots the pairwise LD between each SNP and the common microsatellite alleles, with the strength of LD represented by the P-value for a χ^2 test of association. As can be seen, the pattern of LD with neighboring SNPs is complex, the strength of LD varies for different alleles, and LD may extend long distances.

implemented in PLINK (10). The haplotype with marker rs12682496 gave an omnibus P-value of 2.31×10^{-6} (corrected for 61 SNPs, $P = 1.41 \times 10^{-4}$), with the allele 6-rs12682496 C haplotype being strongly associated with ALS ($P = 1.05 \times 10^{-6}$). This haplotype was also associated with ALS in each of the study populations.

Mutagenesis screen in *Drosophila*

In parallel, and independently of the genetic association study, we performed a forward ethyl methanesulphonate (EMS)-based mutagenesis screen in *Drosophila* using eyFLP technology (11) to discover genes involved in synaptic transmission and neuronal survival or development (12). We retained 138 mutants with defective ‘on’ and ‘off’ transients as candidate mutants (12). Mutations identified using this screening strategy usually affect well-characterized processes involved in presynaptic function, including exocytosis, endocytosis and neuronal survival (13,14).

One of the complementation groups encompassed two lethal alleles showing striking electroretinogram (ERG) phenotypes. The photoreceptor layer depolarized less in response to a one second light pulse and the on and off transients were also dramatically reduced when compared to controls, suggesting abnormal neuronal communication (Fig. 2A and B).


To analyze the integrity of the homozygous mutant photoreceptors, we labeled them with anti-chaoptin (mAb 24B10), an antibody that labels the photoreceptor membrane. In both mutants the R7 and R8 photoreceptors projected into the medulla, but the projection pattern was disrupted and the array of photoreceptor terminals was disordered (Fig. 2C). These data suggest that the defects in neuronal communication we identified might arise, at least in part, from altered axonal targeting and synaptic development.

We mapped the mutants to cytological interval 24F2 of the *Drosophila* genome and found close linkage to P-element KG05280. We confirmed this with a complementation test using a cytologically mapped deficiency uncovering several genes in this region (Fig. 2D) (15). Sequencing of 20 kb genomic DNA surrounding KG05280 (Fig. 2E) revealed mutations R475K (*elp3¹*) and R456K (*elp3²*) in *Drosophila* *ELP3* (Fig. 2F). This gene is highly homologous to human *ELP3*, being 82% identical and 91% similar. Both mutated arginines are conserved across species and are part of the signature sequence of the GCN5-related acetyl transferase (GNAT) domain of the enzyme (Fig. 2G). In a second complementation test, *P{GawB}-NP0434*, a lethal transposon molecularly mapped to the *ELP3* gene, failed to complement *elp3¹* and *elp3²*, further confirming that the lethality of the mutants and the lesions in *ELP3* mapped to the same locus. Taken together, these data independently identify *ELP3* as a critical regulator of axon targeting and synaptic communication, and suggest the GNAT domain plays a significant role in this process. Furthermore, the data suggest that it is a loss of function of *ELP3* that leads to neuronal defects.

ELP3 expression in humans and transgenic mice

All genes so far known to play a causal role in ALS are expressed in motor neurons (16). To explore the functional role of *ELP3*, we examined lumbar spinal cord tissue of people who died of non-neurological conditions by staining with rabbit anti-*ELP3* antibody. We observed *ELP3* protein in human spinal motor neurons Supplementary Material, Fig. S7).

Since *SOD1* mutations remain the most common genetic cause of ALS, we explored the possible changes in *ELP3*



expression in SOD1-mediated ALS. Western blotting revealed robust expression of *ELP3* in the ventral and dorsal part of the spinal cord both in *SOD1^{WT}* and *SOD1^{G93A}* transgenic ALS mice (Supplementary Material, Fig. S8). There was no difference in expression between the two spinal cord regions, and no variation of expression in the ventral cord during disease progression. Immunostaining of the ventral horn showed clear *ELP3* expression in motor neurons (Supplementary Material, Fig. S9).

To elucidate whether a loss of *ELP3* function was indeed the mechanism in the ALS population, we determined levels of *ELP3* expression in carriers of the *ELP3* genetic variants. In human cerebellar tissue from control individuals, 15% more *ELP3* protein was observed in those carrying protection-associated alleles than those carrying risk-associated alleles only ($n = 18$, t -test $P = 0.01$, Fig. 3A and B). In motor cortex from individuals with ALS, 59% more *ELP3* protein was observed in those carrying protection-associated alleles than those carrying risk-associated alleles only ($n = 17$, t -test $P = 0.01$, Fig. 3C and D).

Knockdown of *ELP3* in zebrafish

Based on these findings, we next investigated the significance of a loss of *ELP3* function in a zebrafish model. The protein sequence of *ELP3* is highly conserved in zebrafish, with 91.3% identity and 97.3% similarity to human *ELP3*. Western blot analysis of zebrafish embryos 30 h post-fertilization injected with an *ELP3*-specific RNA-blocking ATG morpholino (ATG-MO), showed a dose-dependent lowering of *ELP3* protein levels (Fig. 4A). In line with axonal targeting defects in *ELP3* mutant *Drosophila* photoreceptors, injection of zebrafish embryos with 6 ng of ATG-MO demonstrated abnormal branching in motor axons in 67.5% of the cases, compared with 17.8% of embryos injected with 6 ng of control morpholino (Ctr-MO, Fig. 4B and C). Similar findings were obtained on injection of 9 ng of an *ELP3*-specific splice-site-targeting morpholino (Sp-MO), which also induced dose-dependent abnormal branching in 63.6% of embryos (Table 2). Moreover, at the highest dose tested the axonal length of ventral motor neuron axons was significantly decreased by 14.7% (ATG-MO) and 18.7% (Sp-MO) (Fig. 4D). This effect too was dose-dependent for both morpholinos [Pearson correlation: -0.49 , $P = 1.83 \times 10^{-12}$ (ATG-MO) and -0.46 , $P = 4.05 \times 10^{-9}$ (Sp-MO)]. Embryos injected with Ctr-MO showed no defects in these parameters compared with buffer-injected embryos.

DISCUSSION

This study provides four lines of evidence implicating the RNA polymerase II component *ELP3* as critically important

to the axonal biology of neurons and supporting the initial observation of involvement in human motor neuron disease. First, in an association study of 1483 individuals, *ELP3* was associated with human motor neuron degeneration in the form of ALS in three different populations. Secondly, an independent mutagenesis screen in *Drosophila* for defects in neuronal communication and survival identified two different loss of function *ELP3* mutations that each conferred abnormal photoreceptor axonal targeting and synaptic development, possibly signifying neurodegeneration. Thirdly, knockdown of *ELP3* in zebrafish using antisense morpholino technology resulted in a dose-dependent shortening and abnormal branching of motor neurons with no concomitant morphological abnormality. Finally, risk-associated *ELP3* alleles were associated with lower brain *ELP3* expression in humans. These findings strongly implicate *ELP3* in axonal biology and as a gene conferring risk of neuronal degeneration.

The published SNP-based genome-wide association studies in ALS have not detected associated *ELP3* variants (4–6), but the protection-associated *ELP3* microsatellite variants have a total frequency of $\sim 11\%$, so approaches using tag-SNPs might not detect them. Although we too did not see any single SNP associations using a dense set of SNPs in and around *ELP3*, we did identify a haplotype between microsatellite allele 6 and the C allele of rs12682496, suggesting either that an untyped causal variant lies on this haplotype or the haplotype itself is functional. Although in general microsatellites are not thought to be functional, differences in gene expression may be conferred by polymorphic microsatellites in regulatory regions (17–19) or in coding sequences (20). Consistent with an important genomic function, the D8S1820 microsatellite repeat is conserved within *ELP3* in chimpanzees and rhesus monkeys, which suggests that it predates the common ancestor of apes and rhesus monkeys and is therefore at least 25 million years old.

The *ELP3* protein is part of the RNA polymerase II complex and is involved in RNA processing (Supplementary Material, Table S5) (21). It contains an Fe₄S₄ cluster and is involved in histone acetylation (22), RNA elongation (21), modification of tRNA wobble nucleosides (23) and an unknown catalytic function related to free radical reactions. Alteration in RNA processing is an element in the pathophysiology of several motor neuron disorders and neurodegenerative diseases, including ALS (2,24,25), hereditary motor neuronopathies 5 [MIM600794] and 6 [MIM604320], Charcot–Marie–Tooth disease type 2D [MIM601472], spinal muscular atrophy [MIM253300], familial dysautonomia [MIM223900] (26) and spinocerebellar ataxia 7 [MIM164500] (27) (Supplementary Material, Table S5). In addition, trinucleotide repeat neurodegenerative diseases have been proposed to be the result of a disruption of nuclear organization that prevents proper RNA processing.

Figure 2. *Drosophila ELP3* mutants identified in a screen for defects in neuronal communication. (A and B) ERG recordings and quantification of ‘on’ and ‘off’ (arrowheads in A) amplitudes of control and *ELP3* mutant eyes. Black: on- and grey off-transients. Controls $n = 48$, *elp3¹* $n = 59$, *elp3²* $n = 57$. Error bars indicate standard error of the mean. t -test: Control-*elp3¹*, on: $P = 1.86 \times 10^{-16}$, off: $P = 1.78 \times 10^{-14}$; control-*elp3²*, on: $P = 1.58 \times 10^{-19}$, off: $P = 7.90 \times 10^{-10}$. (C) Confocal microscopy showing the photoreceptor axon projections in the medulla labeled with anti-chaoptin. In the mutants photoreceptors arrive and synapse in the medulla, but the synapses are not properly organized in rows. Scale bars 20 μ m. (D) Mapping of *ELP3* mutations. KG P-elements used for fine-mapping located in the 24C5-8 cytological region. Numbers under markers are tested/recombinant flies. (E) Recombination distances (cM) for the three P-elements closest to the mutant phenotype (lethality). The position of *ELP3* in relation to KG05280 is indicated with a red asterisk and the 20 kb sequenced region as a grey bar. (F) *ELP3* mutations (arrows). No mutations were found in surrounding genes. (G) Schematic representation of fly *ELP3* (552aa) and mutations *elp3¹* and *elp3²*.




Figure 3. Western blot analysis of ELP3 protein expression in human control cerebellar tissue and ALS motor cortex. (A) Western blot analysis of cerebellar tissue samples from controls carrying risk-associated alleles (Risk) or at least one protection-associated allele (Protection). (B) Expression of ELP3 protein as a ratio to β -actin in cerebellar tissue from controls carrying risk-associated alleles (triangles, $n = 13$) or at least one protection-associated allele (diamonds, $n = 5$). (C) Western blot analysis of ALS motor cortex tissue samples carrying risk-associated alleles (Risk) or at least one protection-associated allele (Protection). (D) Expression of ELP3 protein as a ratio to β -actin in ALS motor cortex samples carrying risk-associated alleles (triangles, $n = 9$) or at least one protection-associated allele (diamonds, $n = 8$).

A possible explanation for ELP3 involvement in motor neuron degeneration comes from its effect on transcription through histone acetylation. Heat shock proteins (HSPs) are molecular chaperones whose expression is increased in response to cellular stress. Motor neurons have a high threshold for activating HSPs, making them particularly vulnerable to stressors, including mutant *SOD1* (28). ELP3 directly regulates HSP70 expression by acetylation of histones H3 and H4 (29), and therefore one possible explanation for the association of high-expressing *ELP3* alleles with protection from motor neuron degeneration in humans is the ability to increase the transcription of HSP70. Indeed, intraperitoneal injection of HSP70 prolonged the lifespan of G93A *SOD1* transgenic mice (30).

The association of *ELP3* variants with motor neuron degeneration and axonal biology in general increases the evidence that the RNA processing pathway is of particular importance to neurons, and provides a potential therapeutic target for treatment of ALS.

MATERIALS AND METHODS

Study patients

Three geographically distinct populations were studied, from the UK, Belgium and the US (Supplementary Material, Table S1). All individuals were of European ancestry. Individuals attending specialist ALS clinics in each participating center were invited to participate. The diagnosis of ALS was made according to the El Escorial criteria after full investigation to exclude other causes. Patients with familial ALS were excluded but samples were not routinely screened for *SOD1* mutations. Controls were unrelated individuals




Figure 4. Morpholino-induced knockdown of ELP3 affects motor neuron axonal branching and length. (A) Western blot of ELP3 following treatment with Ctr-MO and ATG-MO. Maximal ELP3 knockdown was 44%. (B) ELP3 knockdown by Sp-MO and ATG-MO resulted in increased branching of motor axons (right) compared with control (left). (C) There was a dose-dependent decrease in axonal length of motor neurons for both Sp-MO and ATG-MO. Results show SEM (* $P < 0.01$; ** $P < 1.0 \times 10^{-7}$). P -values at each dose of ATG-MO compared with 6.0 ng Ctr-MO were 3.0 ng: $P = 0.0024$; 4.5 ng: $P = 1.19 \times 10^{-8}$; 6.0 ng: $P = 7.68 \times 10^{-11}$. P -values at each dose of Sp-MO compared with 6.0 ng Ctr-MO were 6.0 ng: $P = 0.0084$; 7.5 ng: $P = 0.0039$; 9.0 ng: $P = 6.94 \times 10^{-9}$. Scale bar 50 μ m.

travelling with the patient. In the UK samples, 31% were blood donors from the same geographical region. The study was ethically approved by the institutional review board of each participating institution.

Genetic association methods

We used a dual strategy to select microsatellite markers. Using the program MaGIC (31) we generated one set of markers to target genes and regions from candidate pathways based on existing hypotheses of ALS causation and a second set to target gene-dense regions throughout the genome. We used an initial DNA pooling strategy in the UK samples to prioritize the microsatellite markers for further study by conventional genotyping of individual DNA samples. DNA pools were made by standard methods (32), with each pool comprising non-overlapping samples grouped by phenotype. The smallest pool comprised 57 individuals and the largest 123. Microsatellite genotypes were analyzed by electrophoresis of fluorescently labeled PCR products using an Applied Biosystems ABI 3100 or 3130XL Genetic Analyzer (UK, Belgium) or LiCor Genotyping System (USA). Pool quality was validated by allele frequency estimation of microsatellite alleles and SNPs (33). The results

Table 2. Knockdown of *ELP3* in Zebrafish

	Embryos showing >2/20 branching axons (%) ^a	Odds ratio (CI) compared with Ctr-MO	χ^2 P-value	Branching axons per embryo (%) ^b
Ctr-MO (6.0 ng), n = 45	17.8			4.1
ATG-MO (3.0 ng), n = 35	48.6	4.4 (1.6–12.0)	0.003	8.7
ATG-MO (4.5 ng), n = 61	50.8	4.8 (1.9–11.9)	4.89×10^{-4}	9.4
ATG-MO (6.0 ng), n = 40	67.5	9.6 (3.5–26.4)	3.34×10^{-6}	10.1
Sp-MO (6.0 ng), n = 38	28.9	1.9 (0.7–5.3)	0.23	5.4
Sp-MO (7.5 ng), n = 37	37.8	2.8 (1.0–7.8)	0.04	7.3
Sp-MO (9.0 ng), n = 33	63.6	8.1 (2.9–23.0)	3.47×10^{-5}	12.0

Table showing knockdown of *ELP3* using two different antisense morpholinos results in dose-dependent abnormal branching of primary motor neurons.

^aFor ATG-MO, Spearman correlation: 0.33 ($P = 5.28 \times 10^{-6}$), Kruskal–Wallis test $P = 5.33 \times 10^{-5}$; for Sp-MO, Spearman correlation: 0.33 ($P = 2.57 \times 10^{-5}$), Kruskal–Wallis test $P = 3.80 \times 10^{-4}$.

^bFor ATG-MO, Spearman correlation: 0.30 ($P = 3.21 \times 10^{-5}$), Kruskal–Wallis test $P = 1.35 \times 10^{-4}$; for Sp-MO Spearman correlation: 0.38 ($P = 1.36 \times 10^{-6}$), Kruskal–Wallis test $P = 3.91 \times 10^{-5}$.

were ranked in order of statistical significance using a measure that included factors for pooling and genotyping artifacts. We gave highest priority for follow-up to adjacent markers in the top 1% of results. Prioritized markers were genotyped in the individual UK samples for confirmation. Confirmed associations were then genotyped in the individual Belgian samples, and replicated results further validated in the US samples, also by typing each DNA individually. Replicated associations were then analyzed further in the study populations by fine-mapping of relevant loci with SNPs.

The D8S1820 dinucleotide repeat alleles were numbered sequentially from the smallest (90 bp=allele 1) to the largest (118 bp=allele 15) for PCR products amplified using the amplimers at <http://www.gdb.org>. SNPs were analyzed by fluorescent end-point PCR using a TaqMan assay or the Illumina 317K Human Infinium array.

Protein studies of human tissue

Brain samples. Cerebellar tissue samples were obtained from non-Alzheimer disease control brains from the Alzheimer's Disease Research Center at Massachusetts General Hospital. ALS tissue samples were obtained from the Medical Research Council Brain Bank at the MRC Centre for Neurodegeneration Research, King's College London. Brain tissue homogenates were prepared using a hand-held homogenizer in RIPA buffer [50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 12 mM deoxycolic acid] containing protease inhibitors (Roche Applied Science, Wellesley, MA). Bradford protein concentration assays were carried out using standard protocols. Rabbit anti- β -actin was obtained from Sigma, St Louis, MO. Blots were incubated with horse-radish peroxidase-coupled secondary anti-rabbit antibody (Jackson ImmunoResearch, West Grove, PA) or secondary anti-rabbit alkaline phosphatase-coupled antibody (Sigma). Semi-quantitative analysis of ELP3 and β -actin protein levels was carried out by scanning of western blots and densitometry analysis using Scion Image or ImageQuant software. Each sample was tested between two and eight times.

Spinal cord samples. Paraffin-embedded spinal cord tissue of controls were stained with rabbit anti-ELP3 antibody and visualized using 3,3'-diaminobenzidine tetrahydrochloride (Sigma).

Western blotting. Western blotting was performed using primary rabbit polyclonal anti-ELP3 antibody raised against gel-purified GST-(yeast) ELP3, rabbit polyclonal anti-ELP3 antibody raised against specific peptide sequences of human ELP3 (CPGGPDSDFEYSTQSY and HKVRPYQVELVRR-DYV) and rabbit anti- β -actin.

Transgenic mice

B6SJLTgN (*SOD1*^{WT}) and B6SJLTgN (*SOD1*^{G93A})1Gur transgenic mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Spinal cord was dissected and homogenized in RIPA buffer. Western blotting was performed using primary antibodies of rabbit polyclonal anti-ELP3 antibody raised against gel-purified GST-ELP3 and mouse monoclonal anti- β -actin antibody (Sigma). Blots were incubated with either secondary anti-rabbit or anti-mouse alkaline phosphatase-coupled antibody (Sigma). Immunohistochemical studies of spinal cord were performed on transgenic *SOD1*^{G93A} and age-matched transgenic *SOD1*^{WT} mice. Fresh frozen sections were co-stained with mouse anti-SMI32 (Sternberger Monoclonals) and rabbit anti-ELP3 antibody. The sections were incubated with either Alexa Fluor 488 anti-mouse or AlexaFluor 555 anti-rabbit secondary antibody (Molecular Probes).

Drosophila methods

Mutagenesis and phenotyping. Flies were grown on standard molasses medium. We performed a forward EMS-based mutagenesis screen using the eyFLP technology (11) to discover genes involved in synaptic transmission and neuronal survival or development (12). Mutant flies were tested using a counter-current phototaxis assay to retain blind flies, and using ERG field potential recordings of the eye during a light flash, to determine synaptic transmission efficiency (12). In a normal fly eye, six of the eight photoreceptors of each ommatidium (R1–R6) project into the first optic ganglion, the lamina, while the other two (R7 and R8) project deeper into the second optic ganglion, the medulla, in a stereotyped manner. Examination of this projection pattern allows the quick assessment of changes in neuronal targeting or gross synaptic structure (34). KG P-elements for mapping were obtained from the Bloomington

Stock Center, IN, USA. The ELP3 mutants *yw eyFLP GMRLacZ; elp3¹ or ² P{y⁺}FRT40A^{iso}/CyO, Kr::Gal4 UAS::GFP* and controls *yw eyFLP GMRLacZ; P{y⁺}FRT40A^{iso}* were crossed to *yw eyFLP GMRLacZ; cl2L P{w⁺}FRT40A/CyOP{y⁺}* to create flies with homozygous ELP3 mutant or wild-type control eyes. For sequencing, *yw eyFLP GMRLacZ; elp3¹ or ² P{y⁺}FRT40A^{iso}/CyO, Kr::Gal4 UAS::GFP* animals were crossed to *yw eyFLP GMRLacZ; P{y⁺}FRT40A^{iso}*. ERGs and immunohistochemistry on adult brains were performed as described (14,20). The lethal insertion *P{GawB}NP0434* that fails to complement mutant ELP3 alleles was obtained from the Kyoto *Drosophila* Genetic Resource Center, Japan. For sequencing, *yw eyFLP GMRLacZ; elp3¹ or ² P{y⁺} FRT40A^{iso}/CyO, Kr::Gal4 UAS::GFP* animals were crossed to *yw eyFLP GMRLacZ; P{y⁺} FRT40A^{iso}* and heterozygous DNA was amplified using PCR, sequenced and analysed with Seqman (DNASTar). To identify the gene mutated, we determined the recombination distance between the lethal lesions and molecularly mapped markers on the chromosome (P-elements).

Immunohistochemistry. Anti-chaoptin serum (mAb 24B10) was obtained from the Developmental Studies Hybridoma Bank and used at a concentration of 1:200; secondary Alexa 555 conjugated antibodies were used at a concentration of 1:200 (Invitrogen). Images were captured using a Radiance BioRad confocal microscope and processed with ImageJ and Photoshop 7.0.

Zebrafish methods

Adult zebrafish and embryos were maintained and staged as described (35). The following morpholinos to knock down the expression of zebrafish ELP3 were obtained from Gene Tools (LLC, Corvallis): An ATG-morpholino targeting the ATG start codon: 5'-TGGCTTCCCATCTTAGACACAAT C-3' (ATG-MO), a splice morpholino targeting a splice site: 5'-CTCAAGTCACCTGACGTATAAAACA-3' (Sp-MO). A reversed ATG sequence 5'-CTAACACAGATTCTACCCTTT CGGT-3' (Ctr-MO) was a control. Morpholinos were injected using a FemtoJet® (Eppendorf). The data shown in this manuscript were obtained by injecting, at the highest doses used, a total of 6, 6 and 9 ng for ATG-MO, Ctr-MO and Sp-MO, respectively. Primary antibodies for western blot analyses of whole embryos 30 h post-fertilization were rabbit anti-Elp3 and anti- α -tubulin (Sigma). The blots were incubated with either secondary anti-rabbit or anti-mouse alkaline phosphatase-coupled antibody (Sigma). Axonal defects were evaluated as described (36). Embryos were scored as affected when two or more axons of the 20 analyzed per embryo (ten rostral, ventral motor nerves per hemisegment along the yolk sac extension) showed branching.

All animal studies were approved by the institutions in which they took place.

Statistical methods

Ranking of microsatellite associations for individual genotyping. DNA pool genotypes were analyzed by a modification of the meta-regression procedure in STATA 8.0 (Stata Inc.) (37). The pool estimate of frequency was analyzed for each allele

and the best *P*-value per marker used to rank the results. The regression equation was $F = \beta_c C + \beta_a A + \beta_s S + K$, where *F* was the pool allele frequency, *C* was 1 for case, 0 for control, *A* was pool mean age of onset or sample acquisition for a control and *S* was the proportion of males. A test of the hypothesis that $\beta_c = 0$ yielded the test statistic. Results were ranked by the size of the statistic. The sampling variance was $pq/2N$. The main source of error in pooled analysis of microsatellite genotypes is the degree of stutter (false bands of lower intensity representing PCR products in which one or more repeats has been lost) and differential amplification (the degree to which smaller alleles are amplified preferentially to larger alleles in PCR reactions). These errors were estimated from data for 400 microsatellite markers typed in 16 individuals, and the expected resulting error for the pooled genotypes was modeled in *Mx* (38). This was $\sigma^2 = 0.215^2 p(1-p)^{1.476}$ for trinucleotide and tetranucleotide repeats, and $\sigma^2 = 0.171^2 p(1-p)^{1.379}$ for dinucleotide repeats.

Individual genotyping. Microsatellites are multi-allelic. Because the multiple ways different alleles can be combined increases the chances of finding an association, an unbiased approach is required that accounts for the inherent multiple testing. We therefore used the permutation-based χ^2 test implemented in the program CLUMP, which was written specifically for the association analysis of multi-allelic markers (39). Stratified analyses of all populations were performed by Fisher's method for combining *k* *P*-values, $\chi^2_k = -2 \sum_1^k \ln(P)$ for CLUMP-derived *P*-values and the Mantel-Haenszel χ^2 test for all other tests. Unstratified analyses were performed by treating the three populations as one. Single SNP and haplotypic association analyses were carried out using PLINK (10) and visualized in Haploview (40). Population structure was analyzed using a χ^2 sum statistic for 99 unlinked markers, estimation of Wright's coefficient *F*_{ST} assuming a single population, and using the program Structure (41).

Protein expression. Semi-quantitative western blot data were log-transformed to normal. Normality was tested by inspection of standardized residual plots, histograms and the Kolmogorov-Smirnov test (*P* = 0.15). Equal variances were tested by Levene's test for homogeneity of variances (*P* = 0.13). Analysis was by homoscedastic *t*-test. Two-tailed *P*-values were reported.

Zebrafish. Zebrafish morpholino experiments were analyzed by χ^2 test, Pearson or Spearman correlation and Kruskal-Wallis tests in the program SPSS 13.0 (SPSS Inc., IL, USA).

ACKNOWLEDGEMENTS

We are indebted to H.J. Bellen, P. Tilkin, RN and A. D'Hondt, RN. We thank Jesper Q. Svejstrup for donation of anti-ELP3 antibody, the Developmental Studies Hybridoma Bank, Iowa for antibodies, the Bloomington Stock Center and Kyoto Genetics Resource Center for flies and Cathryn Lewis and Jean-Marc Gallo for comments.

Conflict of Interest statement. None declared.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at HMG Online.

FUNDING

This work was supported by the Medical Research Council (UK) to A.A.-C.; ALS Association to A.A.-C. and R.H.B.; Motor Neurone Disease Association to A.A.-C.; University of Leuven to W.R.; the Belgian government (Interuniversity Attraction Poles Programme 6/43—Belgian State—Belgian Science Policy) to W.R.; VIB to W.R. and P.V.; the Robert Packard Center for ALS Research to W.R.; the Howard Hughes Medical Institute to H.R.H.; The National Institutes of Neurological Disease and Stroke to R.H.B.; the National Institute on Aging to R.H.B.; the Al-Athel ALS Research Foundation to R.H.B.; the ALS Therapy Alliance to R.H.B., the Angel Fund to R.H.B.; Project ALS to R.H.B.; and the Pierre L. de Bourgnicht ALS Research Foundation to R.H.B. For much of this work, A.A.-C. was a Medical Research Council (MRC) Clinician Scientist Fellow and C.L.S. was funded by GKT PhD Studentship. P.S. and H.R.H. were supported by the Howard Hughes Medical Institute. W.R. was supported through the E von Behring Chair for Neuromuscular and Neurodegenerative Disorders. P.V. was supported through a Marie Curie Excellence Grant. Funding to pay the Open Access Charge was provided by the Medical Research Council.

REFERENCES

- Simpson, C.L. and Al-Chalabi, A. (2006) Amyotrophic lateral sclerosis as a complex genetic disease. *Biochim. Biophys. Acta*, **1762**, 973–985.
- Sreedharan, J., Blair, I.P., Tripathi, V.B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J.C., Williams, K.L., Buratti, E. *et al.* (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science*, **319**, 1668–1672.
- Kabashi, E., Valdmanis, P.N., Dion, P., Spiegelman, D., McConkey, B.J., Velde, C.V., Bouchard, J.P., Lacomblez, L., Pochigaeva, K., Salachas, F. *et al.* (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat. Genet.*, **40**, 572–574.
- Schymick, J.C., Scholz, S.W., Fung, H.C., Britton, A., Arepalli, S., Gibbs, J.R., Lombardo, F., Matarin, M., Kasperaviciute, D., Hernandez, D.G. *et al.* (2007) Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. *Lancet Neurol.*, **6**, 322–328.
- Dunckley, T., Huentelman, M.J., Craig, D.W., Pearson, J.V., Szlinger, S., Josphipura, K., Halperin, R.F., Stamper, C., Jensen, K.R., Letizia, D. *et al.* (2007) Whole-genome analysis of sporadic amyotrophic lateral sclerosis. *N. Engl. J. Med.*, **357**, 775–788.
- van Es, M.A., Van Vught, P.W., Blauw, H.M., Franke, L., Saris, C.G., Andersen, P.M., Van Den Bosch, L., de Jong, S.W., van 't Slot, R., Birve, A. *et al.* (2007) ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. *Lancet Neurol.*, **6**, 869–877.
- van Es, M.A., van Vught, P.W., Blauw, H.M., Franke, L., Saris, C.G., Van den Bosch, L., de Jong, S.W., de Jong, V., Baas, F., van 't Slot, R. *et al.* (2008) Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. *Nat. Genet.*, **40**, 29–31.
- Cronin, S., Berger, S., Ding, J., Schymick, J.C., Washecka, N., Hernandez, D.G., Greenway, M.J., Bradley, D.G., Traynor, B.J. and Hardiman, O. (2007) A genome-wide association study of sporadic ALS in a homogenous Irish population. *Hum. Mol. Genet.*, **17**, 768–774.
- Payseur, B.A., Place, M. and Weber, J.L. (2008) Linkage disequilibrium between STRPs and SNPs across the human genome. *Am. J. Hum. Genet.*, **82**, 1039–1050.
- Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., Bender, D., Maller, J., Sklar, P., de Bakker, P.I.W., Daly, M.J. *et al.* (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.*, **81**, 559–575.
- Newsome, T.P., Asling, B. and Dickson, B.J. (2000) Analysis of *Drosophila* photoreceptor axon guidance in eye-specific mosaics. *Development*, **127**, 851–860.
- Koh, T.W., Verstreken, P. and Bellen, H.J. (2004) Dap160/intersectin acts as a stabilizing scaffold required for synaptic development and vesicle endocytosis. *Neuron*, **43**, 193–205.
- Guo, X., Macleod, G.T., Wellington, A., Hu, F., Panchumarthi, S., Schoenfield, M., Marin, L., Charlton, M.P., Atwood, H.L. and Zinsmaier, K.E. (2005) The GTPase dMiro is required for axonal transport of mitochondria to *Drosophila* synapses. *Neuron*, **47**, 379–393.
- Verstreken, P., Ly, C.V., Venken, K.J., Koh, T.W., Zhou, Y. and Bellen, H.J. (2005) Synaptic mitochondria are critical for mobilization of reserve pool vesicles at *Drosophila* neuromuscular junctions. *Neuron*, **47**, 365–378.
- Zhai, R.G., Hiesinger, P.R., Koh, T.W., Verstreken, P., Schulze, K.L., Cao, Y., Jafar-Nejad, H., Norga, K.K., Pan, H., Bayat, V. *et al.* (2003) Mapping *Drosophila* mutations with molecularly defined P element insertions. *Proc. Natl Acad. Sci. USA*, **100**, 10860–10865.
- Pasinelli, P. and Brown, R.H. (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. *Nat. Rev. Neurosci.*, **7**, 710–723.
- Fuchs, J., Tichopad, A., Golub, Y., Munz, M., Schweitzer, K.J., Wolf, B., Berg, D., Mueller, J.C. and Gasser, T. (2007) Genetic variability in the SNCA gene influences α -synuclein levels in the blood and brain. *FASEB J.*, **22**, 1327–1334.
- Hammock, E.A. and Young, L.J. (2005) Microsatellite instability generates diversity in brain and sociobehavioral traits. *Science*, **308**, 1630–1634.
- Yim, J.J., Ding, L., Schaffer, A.A., Park, G.Y., Shim, Y.S. and Holland, S.M. (2004) A microsatellite polymorphism in intron 2 of human Toll-like receptor 2 gene: functional implications and racial differences. *FEMS Immunol. Med. Microbiol.*, **40**, 163–169.
- Kizawa, H., Kou, I., Iida, A., Sudo, A., Miyamoto, Y., Fukuda, A., Mabuchi, A., Kotani, A., Kawakami, A., Yamamoto, S. *et al.* (2005) An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. *Nat. Genet.*, **37**, 138–144.
- Winkler, G.S., Petrakis, T.G., Ethelberg, S., Tokunaga, M., Erdjument-Bromage, H., Tempst, P. and Svejstrup, J.Q. (2001) RNA polymerase II elongator holoenzyme is composed of two discrete subcomplexes. *J. Biol. Chem.*, **276**, 32743–32749.
- Winkler, G.S., Kristjuhan, A., Erdjument-Bromage, H., Tempst, P. and Svejstrup, J.Q. (2002) Elongator is a histone H3 and H4 acetyltransferase important for normal histone acetylation levels in vivo. *Proc. Natl Acad. Sci. USA*, **99**, 3517–3522.
- Huang, B., Johansson, M.J. and Bystrom, A.S. (2005) An early step in wobble uridine tRNA modification requires the Elongator complex. *RNA*, **11**, 424–436.
- Chen, Y.Z., Bennett, C.L., Huynh, H.M., Blair, I.P., Puls, I., Irobi, J., Dierick, I., Abel, A., Kennerson, M.L., Rabin, B.A. *et al.* (2004) DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). *Am. J. Hum. Genet.*, **74**, 1128–1135.
- Greenway, M.J., Andersen, P.M., Russ, C., Ennis, S., Cashman, S., Donaghy, C., Patterson, V., Swingler, R., Kieran, D., Prehn, J. *et al.* (2006) ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. *Nat. Genet.*, **38**, 411–413.
- Anderson, S.L., Coli, R., Daly, I.W., Kichula, E.A., Rork, M.J., Volpi, S.A., Ekstein, J. and Rubin, B.Y. (2001) Familial dysautonomia is caused by mutations of the IKAP gene. *Am. J. Hum. Genet.*, **68**, 753–758.
- Helmlinger, D., Hardy, S., Sasorith, S., Klein, F., Robert, F., Weber, C., Miguet, L., Potier, N., Van-Dorsselaer, A., Wurtz, J.M. *et al.* (2004) Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. *Hum. Mol. Genet.*, **13**, 1257–1265.
- Batulan, Z., Shinder, G.A., Minotti, S., He, B.P., Doroudchi, M.M., Nalbantoglu, J., Strong, M.J. and Durham, H.D. (2003) High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. *J. Neurosci.*, **23**, 5789–5798.

29. Han, Q., Lu, J., Duan, J., Su, D., Hou, X., Li, F., Wang, X. and Huang, B. (2008) Gcn5- and Elp3-induced histone H3 acetylation regulates hsp70 gene transcription in yeast. *Biochem. J.*, **409**, 779–788.
30. Gifondorwa, D.J., Robinson, M.B., Hayes, C.D., Taylor, A.R., Prevette, D.M., Oppenheim, R.W., Caress, J. and Milligan, C.E. (2007) Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. *J. Neurosci.*, **27**, 13173–13180.
31. Simpson, C.L., Hansen, V.K., Sham, P.C., Collins, A., Powell, J.F. and Al-Chalabi, A. (2004) MaGIC: a program to generate targeted marker sets for genome-wide association studies. *Biotechniques*, **37**, 996–999.
32. Sham, P., Bader, J.S., Craig, I., O'Donovan, M. and Owen, M. (2002) DNA Pooling: a tool for large-scale association studies. *Nat. Rev. Genet.*, **3**, 862–871.
33. Simpson, C.L., Knight, J., Butcher, L.M., Hansen, V.K., Meaburn, E., Schalkwyk, L.C., Craig, I.W., Powell, J.F., Sham, P.C. and Al-Chalabi, A. (2005) A central resource for accurate allele frequency estimation from pooled DNA genotyped on DNA microarrays. *Nucleic Acids Res.*, **33**, e25.
34. Clandinin, T.R. and Zipursky, S.L. (2002) Making connections in the fly visual system. *Neuron*, **35**, 827–841.
35. Westerfield, M. (2003) *The Zebrafish Book*. The University of Oregon Press, Eugene, Oregon.
36. Lemmens, R., Van Hoecke, A., Hersmus, N., Geelen, V., D'Hollander, I., Thijs, V., Van Den Bosch, L., Carmeliet, P. and Robberecht, W. (2007) Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. *Hum. Mol. Genet.*, **16**, 2359–2365.
37. Knight, J. and Sham, P. (2006) Design and analysis of association studies using pooled DNA from large twin samples. *Behav. Genet.*, **36**, 665–677.
38. Neale, M.C., Boker, S.M., Xie, G. and Maes, H.H. (2003) *Mx: Statistical Modeling*, Box 980126 MCV. Richmond, VA, 23298.
39. Sham, P.C. and Curtis, D. (1995) Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. *Ann. Hum. Genet.*, **59**, 97–105.
40. Barrett, J.C., Fry, B., Maller, J. and Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*, **21**, 263–265.
41. Pritchard, J.K., Stephens, M. and Donnelly, P. (2000) Inference of population structure using multilocus genotype data. *Genetics*, **155**, 945–959.